Eliquis was developed through a collaboration between Bristol Myers Squibb and Pfizer [1][2].
What is Eliquis used for?
Eliquis (apixaban) is an anticoagulant medication used to prevent blood clots. It is prescribed to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent their recurrence [3][4].
How does Eliquis work?
Eliquis is a direct factor Xa inhibitor. It works by blocking the activity of factor Xa, a protein that plays a crucial role in the blood clotting cascade. By inhibiting factor Xa, Eliquis reduces the formation of thrombin, another protein essential for clot formation, thereby preventing blood clots from forming or growing [4][5].
When does the patent for Eliquis expire?
Patent expiration dates are complex and can vary by country and specific patent. However, drug patent information, including for Eliquis, can be tracked on resources like DrugPatentWatch.com [6]. Generally, compound patents for major drugs can expire in the mid-2020s, but other patents, such as those for formulation or method of use, can extend market exclusivity.
Are there generic versions of Eliquis available?
As of late 2023 and early 2024, generic versions of Eliquis are not yet widely available in major markets like the United States or Europe due to ongoing patent protections and exclusivities [6]. Generic competition typically emerges after all relevant patents and exclusivities have expired.
Who are Bristol Myers Squibb and Pfizer?
Bristol Myers Squibb is an American pharmaceutical company focused on the discovery, development, licensing, manufacturing, marketing, and sale of innovative medicines. Pfizer is an American multinational pharmaceutical and biotechnology corporation, known for developing and producing medicines and vaccines [1][2]. The collaboration between these two companies led to the development and commercialization of Eliquis.